Keyword: Calquence

The CD22-directed cytotoxin treatment is AstraZeneca's second approved blood cancer asset, with peak sales estimated at about $500 million.

Months ahead of the FDA decision date, the agency approved AbbVie and J&J's Imbruvica, plus Roche's Rituxan, to treat adults with a rare blood cancer.

Imbruvica is the only treatment for Waldenström's macroglobulinemia patients. But before competition hits, its makers are pushing for a wider market.

AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.

J&J and AbbVie racked up new long-term Imbruvica data that will come in handy as they try to ward off a new AstraZeneca competitor.